Gastritis primary prevention

Gastritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Gastritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Diagnostic tests Endoscopic tests Nonendoscopic tests
X Ray
CT
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Gastritis primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Gastritis primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Gastritis primary prevention
CDC on Gastritis primary prevention
Gastritis primary prevention in the news
Blogs on Gastritis primary prevention
Directions to Hospitals Treating Gastritis
Risk calculators and risk factors for Gastritis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Aravind Reddy Kothagadi M.B.B.S[3]

Overview

Primary prevention aims to reduce the incidence and progression of gastritis before mucosal injury or malignant transformation occurs. The cornerstone of primary prevention for the most common form—H. pylori-associated gastritis—is testing for and eradicating the organism, particularly in high-risk populations. A 2025 systematic review and meta-analysis found that H. pylori eradication therapy reduced the relative risk of gastric cancer to 0.64 (95% CI 0.48–0.84) in healthy H. pylori-positive individuals compared with placebo or no therapy. Additional preventive strategies include avoidance or mitigation of known mucosal irritants (NSAIDs, aspirin, alcohol, tobacco), appropriate gastroprotection with proton pump inhibitors (PPIs) for at-risk patients requiring NSAIDs, early identification of individuals predisposed to autoimmune gastritis, and stress ulcer prophylaxis in critically ill patients.

Primary Prevention

1. Prevention of Helicobacter pylori-Associated Gastritis

H. pylori infects approximately 43% of the global population, with prevalence exceeding 60–70% in many low- and middle-income countries. The Maastricht VI/Florence Consensus (2022) formally classifies H. pylori gastritis as an infectious disease and recommends treatment for all infected individuals, regardless of the presence of clinical symptoms or complications. Approximately 90% of gastric cancer cases are causally associated with H. pylori, establishing eradication as the primary strategy for gastric cancer prevention.

The 2024 American College of Gastroenterology (ACG) Clinical Practice Guideline on H. pylori management emphasizes that the decision to test for—and treat—H. pylori should be viewed as a single, unified clinical decision rather than two separate steps, and that all patients in whom H. pylori infection is confirmed by a non-serological test should receive eradication therapy followed by a test of cure.

Given that H. pylori is primarily acquired in childhood through fecal-oral and gastric-oral routes, particularly within households and communities with poor sanitation, the following public health measures serve as primary prevention:

• Improve access to clean water and adequate sanitation, particularly in low- and middle-income countries.
• Promote handwashing with soap before food preparation and after use of the toilet.
• Identify and treat H. pylori in household contacts of infected individuals ("familial-based testing"), as intrafamilial transmission is a dominant route of reinfection.
• Avoid practices that facilitate oral-to-oral transmission (e.g., pre-chewing of food for infants).

2. Prevention of NSAID- and Aspirin-Induced Gastritis

Risk Stratification

NSAIDs and aspirin are among the most widely used medications worldwide and are a major cause of acute and chronic gastric mucosal injury. Key risk factors for NSAID-induced gastroduodenal bleeding include:

Prevention Strategies

Evidence-based strategies for reducing the risk of NSAID-induced gastritis and upper gastrointestinal bleeding (UGIB) include:

• Use the lowest effective dose of NSAID for the shortest necessary duration.
• For patients at moderate gastrointestinal risk requiring a nonselective NSAID, co-prescribe a PPI at standard dose.
• For patients at high gastrointestinal risk, use a COX-2 selective inhibitor (e.g., celecoxib) plus a PPI.
• In patients with cardiovascular risk factors who require NSAID therapy, naproxen is the preferred agent.
• In very high-risk patients with both high gastrointestinal and high cardiovascular risk, NSAID therapy should be avoided altogether.
• Test for and eradicate H. pylori before initiating long-term NSAID therapy in NSAID-naïve patients as a primary prophylaxis measure.
• For patients requiring concomitant use of two or more antithrombotic agents, or an antithrombotic agent together with an NSAID, gastroprotection with a PPI is appropriate.

Patients Aged ≥65 Years on NSAIDs

Patients aged 65 years or older using NSAIDs should be considered for gastroprotection with a PPI, as age ≥65 is an independent risk factor for upper gastrointestinal injury in the context of NSAID or aspirin use.

3. Prevention of Stress-Related Gastritis (Stress-Related Mucosal Disease)

Stress-related mucosal disease (SRMD) refers to mucosal erosions and superficial hemorrhages that develop in critically ill patients under extreme physiological stress. The 2024 Society of Critical Care Medicine (SCCM) and American Society of Health-System Pharmacists (ASHP) Guideline for the Prevention of Stress-Related Gastrointestinal Bleeding in Critically Ill Adults provides the following evidence-based recommendations:

• Coagulopathy, shock, and chronic liver disease are the clinical factors that most likely increase the risk for clinically important stress-related UGIB in critically ill adults.
• Mechanical ventilation alone is not firmly established as an independent risk factor.
• Enteral nutrition probably reduces UGIB risk in critically ill patients and should be initiated early when feasible.
• All critically ill adults with factors that likely increase the risk for stress-related UGIB should receive either a PPI or a histamine-2 receptor antagonist (H2RA) at low dosage to prevent UGIB; the choice between PPI and H2RA should be individualized.
• Stress ulcer prophylaxis should be discontinued when critical illness resolves or the precipitating risk factor is no longer present; discontinuation before ICU transfer is recommended to prevent inappropriate outpatient prescribing.
• Indiscriminate use of stress ulcer prophylaxis in all ICU patients without risk factors is not warranted and carries potential adverse effects (including Clostridioides difficile infection and community-acquired pneumonia).

4. Prevention of Alcohol-Related Gastritis

Chronic and heavy alcohol consumption is a well-established cause of acute and chronic gastritis through direct erosion of the gastric mucosal barrier, increased gastric acid secretion, and impaired mucosal blood flow. Prevention is primarily behavioral and includes:

• Abstinence from or significant reduction of alcohol consumption, with guidance following evidence-based harm reduction frameworks.
• Screening for alcohol use disorder in primary care settings, with referral to appropriate behavioral health services when indicated.
• Avoidance of concomitant NSAID use and heavy alcohol consumption, as these combine synergistically to increase mucosal injury risk.

5. Prevention of Tobacco-Related Gastritis

Tobacco smoking contributes to gastritis through several mechanisms: reduced mucus production, impaired mucosal blood flow, increased gastric acid secretion, and synergistic interaction with H. pylori infection and alcohol. Observational data demonstrate that current smokers have a higher prevalence of clinically significant gastric lesions compared with non-smokers or former smokers. Smoking cessation reduces the risk of complications associated with gastritis and other forms of peptic mucosal disease and is recommended as part of a comprehensive primary prevention strategy.

6. Prevention and Early Identification of Autoimmune Gastritis

Autoimmune gastritis (AAG) results from immune-mediated destruction of the oxyntic mucosa due to anti-parietal cell antibodies (PCA) targeting the H⁺/K⁺-ATPase subunit on parietal cells. Although there is currently no proven primary prevention strategy for AAG itself given its genetic and autoimmune basis, several approaches can reduce progression and identify individuals at risk:

• Active case-finding in individuals with first-degree relatives with AAG or other autoimmune diseases (particularly Hashimoto's thyroiditis and type 1 diabetes mellitus) using serological tests: anti-parietal cell antibody (PCA), anti-intrinsic factor antibody (IFA), serum gastrin-17, and pepsinogen I/II ratio.
• Screening for concurrent H. pylori infection in all patients diagnosed with AAG, with eradication if infection is confirmed, as dual pathology accelerates the progression of atrophy.
• Screening for associated autoimmune conditions in patients with confirmed AAG, including autoimmune thyroid disease and type 1 diabetes.
• Monitoring for micronutrient deficiencies: regular assessment of serum vitamin B12, iron indices, and folate levels to enable early supplementation and prevent irreversible complications (e.g., subacute combined degeneration of the cord).
• Smoking cessation improves symptom management and overall health in patients with or predisposed to AAG.

7. Dietary and Lifestyle Modifications

Although no single dietary factor has been definitively established as causative or preventive for gastritis in large high-quality randomized controlled trials, the following lifestyle recommendations are supported by observational data and guideline consensus:

• Avoid prolonged or irregular fasting and erratic meal patterns
• Avoid or minimize consumption of highly spicy, acidic, or very hot foods and beverages
• Avoid excessive coffee and caffeinated beverage consumption
• Maintain adequate hydration
• Regular moderate physical activity
• Stress reduction techniques (mindfulness, cognitive-behavioral therapy, relaxation exercises)

8. Medication Safety and Drug Review

• Review patients' medication lists regularly to identify and minimize use of medications associated with gastric mucosal injury: NSAIDs, aspirin, anticoagulants, corticosteroids, bisphosphonates, selective serotonin reuptake inhibitors (SSRIs), and potassium supplements.
• Substitute COX-2 selective inhibitors for nonselective NSAIDs in patients with gastrointestinal risk factors when anti-inflammatory therapy is required.
• Test for H. pylori and eradicate if positive before initiating long-term NSAID or aspirin therapy.
• Avoid indiscriminate and prolonged use of NSAIDs without gastroprotective cover in elderly patients or those with a history of peptic ulcer disease.